| Name | Visionworks |
|---|---|
| Organization Name | Visionworks Inc |
| Location | 13371 W Grand Ave, Ste 102, Surprise, Arizona 85374 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (623) 556-8038 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
Following studies showing that cocaine influences the replication and transcription of HIV, a researcher at the George Washington University School of Medicine and Health Sciences was awarded more than $2.3 million from the National Institutes of Health to look deeper into the involved molecular mechanisms that allow this effect to happen.
According to researchers, screening for the AIDS virus to include every American at least once and the highest-risk people once a year could prevent more than 80,000 infections over the next 20 years. The team from Yale University in Connecticut and Stanford University in California reported that if treatment for infected people were integrated into such a program, it would prevent an estimated 212,000 new infections.
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
› Verified 2 days ago
| NPI Number | 1063708352 |
| Organization Name | VISIONWORKS, INC. |
| Doing Business As | VISIONWORKS |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 13371 W Grand Ave, Suite 102, Surprise, AZ 85374 |
| Phone Number | 623-556-8038 |
News Archive
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
Following studies showing that cocaine influences the replication and transcription of HIV, a researcher at the George Washington University School of Medicine and Health Sciences was awarded more than $2.3 million from the National Institutes of Health to look deeper into the involved molecular mechanisms that allow this effect to happen.
According to researchers, screening for the AIDS virus to include every American at least once and the highest-risk people once a year could prevent more than 80,000 infections over the next 20 years. The team from Yale University in Connecticut and Stanford University in California reported that if treatment for infected people were integrated into such a program, it would prevent an estimated 212,000 new infections.
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
› Verified 2 days ago
News Archive
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
Following studies showing that cocaine influences the replication and transcription of HIV, a researcher at the George Washington University School of Medicine and Health Sciences was awarded more than $2.3 million from the National Institutes of Health to look deeper into the involved molecular mechanisms that allow this effect to happen.
According to researchers, screening for the AIDS virus to include every American at least once and the highest-risk people once a year could prevent more than 80,000 infections over the next 20 years. The team from Yale University in Connecticut and Stanford University in California reported that if treatment for infected people were integrated into such a program, it would prevent an estimated 212,000 new infections.
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
› Verified 2 days ago
Osco Drug #977 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 14551 W Grand Ave, Surprise, Arizona 85374 Phone: (623) 546-4085 | |
Cvs Pharmacy #09306 Type: Pharmacy Location: 19505 N Sunrise Blvd, Surprise, Arizona 85374 Phone: (623) 556-4778 | |
Barnet Dulaney Perkins Eye Center Type: Durable Medical Equipment & Medical Supplies Supplier Location: 14239 W Bell Rd 216 & 219, Surprise, Arizona 85374 Phone: (602) 955-1000 | |
Eyes West Optical Inc Type: Eyewear Supplier (Equipment, not the service) Location: 12801 West Bell Road, Surprise, Arizona 85378 Phone: (623) 583-0377 | |
Fine Fittings Type: Durable Medical Equipment & Medical Supplies Supplier Location: 18795n Reems Rd G-113, Surprise, Arizona 85374 Phone: (623) 214-3324 |